Drugs / Oncoquest-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02194751 | Jul 2021 → Jun 2024 | follicular lymphoma | XEME Biopharma Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oncoquest-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02194751 ↗ |
| Modality | Vaccine | “Oncoquest-L vaccine” NCT02194751 ↗ |
| Route | Subcutaneous | “the vaccine will be administered subcutaneously” NCT02194751 ↗ |